Novel Anti-fibrotic Therapies
Fibrosis is a major player in cardiovascular disease, both as a contributor to the development of disease, as well as a post-injury response that drives progression. Despite the identification of many mechanisms responsible for cardiovascular fibrosis, to date no treatments have emerged that have ef...
Main Authors: | Benita L. McVicker, Robert G. Bennett |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00318/full |
Similar Items
-
Reduction in Obesity-Related Hepatic Fibrosis by SR1664
by: Benita L. McVicker, et al.
Published: (2023-09-01) -
A Selective PPARγ Modulator Reduces Hepatic Fibrosis
by: Benita L. McVicker, et al.
Published: (2020-07-01) -
Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism
by: Shuai Yuan, et al.
Published: (2023-04-01) -
p38γ Activation and BGP (Biliary Glycoprotein) Induction in Primates at Risk for Inflammatory Bowel Disease and Colorectal Cancer—A Comparative Study with Humans
by: Harvinder Talwar, et al.
Published: (2020-12-01) -
Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease
by: Yifang Li, et al.
Published: (2022-05-01)